## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Single Technology Appraisal (STA)

## Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

| Version of matrix of consultees and commentators reviewed:              |  |                   |  |   |  |  |  |  |
|---|--|-------------------|--|---|--|--|--|--|
| Provisional matrix of consultees and commentators sent for consultation |  |                   |  |   |  |  |  |  |
| Summary of comments, action taken, and justification of action:         |  |                   |  |   |  |  |  |  |
|   | Proposal:  | Proposal made by: |  | Action taken:  Removed/Added/Not included/Noted | Justification:   |  |  |  |
| 1.  | Add Care Quality Commission to general group commentators. | NICE Secretariat  |  | Added   | Care Quality Commission meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general group commentator. |  |  |  |

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for the technology appraisal of abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

Issue date: September 2010

| 2. | Remove United Kingdom Disabled Person's Council (UKDPC) from patient/carer group consultees.      | NICE Secretariat | Removed | Removed as per specific organisations' request. |
|----|---|------------------|---------|---|
| 3. | Remove Carers UK from patient/carer group consultees.   | NICE Secretariat | Removed | Removed as per specific organisation's request. |
| 4. | Remove SKILL: National Bureau for Students with Disabilities from patient/carer group consultees. | NICE Secretariat | Removed | Removed as per specific organisation's request. |

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for the technology appraisal of abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

Issue date: September 2010